News

On 16th November, the much-anticipated ‘2023 R&D Index of Chinese Pharmaceutical Enterprises’ was unveiled at the China Pharmaceutical Industry Development Conference jointly organised by the Ministry of Industry and Information Technology (MIIT) and the Shanghai Municipal Government, and Autobio was awarded the champion of the R&D Index of the medical device industry for its outstanding performance in R&D Achievement and R&D Support Indexes, and the runner-up in the comprehensive list covering a wide range of pharmaceutical fields. Meanwhile, Autobio also won the second place in the comprehensive list covering a wide range of pharmaceutical fields, demonstrating the company's deep heritage and strong development momentum in the biomedical field.

The 2023 R&D Index of Chinese Pharmaceutical Enterprises is jointly released by five authoritative institutions, namely, China Centre for International Economic Exchanges (CIEE), China Economic Information Service (CEIS) of Xinhua News Agency, China Society of Pharmaceutical Accounting (CSPA), Beijing Jiaotong University (BJTU) Digital Taxation Research Institute (DTRI) and China Pharmaceutical Industry Information Centre (CPII).

The index comprehensively examines and accurately analyses the R&D strength of Chinese pharmaceutical enterprises, and demonstrates to the world China's vitality, profound heritage and extraordinary strength in the field of pharmaceutical research and development. After three sessions of continuous release, the index has become a shining business card in the field of pharmaceutical innovation, providing a precise and intuitive ‘dashboard’ and ‘compass’ for pharmaceutical enterprises on the road ahead.

With 26 years of deep ploughing in the field of IVD industry, Autobio has always put technological innovation in the first place in its strategy, and driven the high-quality development of the enterprise by innovation.

01 High Investment in R&D

Autobio has maintained high R&D investment for many years, and in 2023, it invested 656 million RMB in R&D, accounting for 14.77% of its revenue. Entering 2024, the momentum of R&D investment is unabated, with R&D investment of 511 million yuan in the first three quarters, accounting for 15.1% of operating revenue.

02 R&D Layout

Continuously improve the technology R&D system with Zhengzhou as the centre and Beijing, Shanghai, Shenzhen, Suzhou and North America R&D centres as branches, making full use of the local talent and technology advantages to enter into the development of cutting-edge technologies and products in the field of in vitro diagnostics.

03 R&D Process and Team

Strict innovation management process, comparable to the international advanced, to ensure the excellent performance of products. Currently, Autobio has more than 1,800 R&D personnel, accounting for about one-third of the total number of employees, and has become one of the companies with more R&D personnel and active new product launches in the industry.

04 Innovation Platform Construction

Autobio actively promotes the construction of ‘industry-university-research-medicine’ high-efficiency collaborative innovation ecosystem, joining hands with relevant universities, research institutes and enterprises upstream and downstream of the industrial chain, and taking the lead in the establishment of the National Engineering Research Centre for the Detection of Emerging and Suddenly Emerging Infectious Diseases; taking the lead in the National Key Research and Development Programs of ‘R&D of Nucleic Acid The company has led a number of major national and provincial research projects, such as ‘R&D of instant detection system for ultra-multiple pathogens’ and ‘fully automated system for high-performance laboratory assembly line’, and has achieved rich scientific research results, which have helped the national scientific and technological progress and industrial upgrading, and laid the foundation for the sustainable development of the enterprise.

05 Innovative Achievements

On the basis of continuous high investment in research and development, the company has made a series of innovative achievements: achieved basic self-sufficiency in the core raw materials of immunodiagnostic products; launched a new generation of high-throughput chemiluminescence immunoassay analyser AutoLumo A6000; launched the independently researched and developed laboratory assembly line Autolas X-1 series products, which achieved the leap in the field of laboratory assembly line from the local brand to the local R & D and manufacturing; launched the fully automatic microbial mass spectrometry system; launched the fully automated microbiological mass spectrometry system, which helped the progress of national science and technology and industrial upgrading. The launch of fully automated microbial mass spectrometry detection system, which has built a rich microbial protein fingerprint library, providing locally manufactured high-end products for the rapid and accurate identification of clinical microorganisms; the launch of fully automated nucleic acid purification and real-time fluorescence PCR analysis system, which innovatively realises the complete automation of single-sample on-demand testing, extraction and amplification, providing more convenient and efficient nucleic acid detection products for the medical laboratories. Autobio's products and services are designed to provide medical laboratories with more convenient and efficient nucleic acid testing products.

Taking advantage of its products and services, Autobio has launched intelligent solutions for medical laboratories and intelligent construction solutions for regional medical testing centres, helping the development of intelligent medical laboratories and intelligent regional testing centres in China.

In September this year, Autobio was selected as one of the top 100 enterprises in China's pharmaceutical industry in 2023, and was ranked as the first runner-up in the list of the top 100 enterprises in China's Pharmaceutical Enterprises R&D Index in 2023, which is a high recognition of the company's innovation ability and comprehensive strength. Autobio will continue to adhere to the innovation-driven development strategy and move forward to a new stage of high-quality development with a more determined pace, contributing to the health and well-being of the people and a healthy China.